Peri-implantitis Market Size, Share and Growth Outlook 2026: By Method Type (Surgical, Non-Surgical), By End-User, Companies to 2034.
The global Peri-implantitis Market size is forecast to increase from $1.53 Billion in 2026 to $3.04 Billion in 2034 at a CAGR of 8.96% between 2026 and 2034.
The Peri-implantitis market report provides detailed analysis and outlook of Peri-implantitis segments including By Method Type (Surgical, Non-Surgical), By End-User (Hospitals, Dental Clinics, Others) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.
Peri-Implantitis Industry Overview
Advanced Implant Decontamination and Targeted Therapies Are Transforming Peri-Implantitis Management
The peri-implantitis industry is evolving through the development of minimally invasive implant decontamination technologies, precision immunomodulatory therapies, and biologically targeted treatment strategies. Clinical research is increasingly focused on preserving dental implants by eliminating pathogenic biofilms while minimizing damage to implant surfaces and surrounding tissues. At the same time, advances in molecular biology are enabling the development of localized therapies that address the inflammatory mechanisms responsible for peri-implant bone loss. These innovations are supporting more predictable treatment outcomes and expanding therapeutic options for managing one of the most significant complications associated with dental implant therapy.
Electrolytic Implant Surface Decontamination Gains Clinical Momentum
The industry is witnessing growing adoption of advanced electrolytic technologies designed to improve implant surface cleaning without mechanical damage. Istanbul University expanded its randomized controlled clinical trial evaluating the GalvoSurge system as an adjunctive treatment for peri-implantitis compared with conventional titanium brushes and hydrogen peroxide flap procedures. The study measures clinical outcomes including probing pocket depth, bleeding on probing, and radiographic bone levels over a 24-month follow-up period. Supporting this trend, Straumann Group expanded commercial availability of the GalvoSurge implant care system throughout North America and Europe. The technology generates a localized hydrogen burst through an electrolytic fluid system that removes complex subgingival bacterial biofilms from titanium implant surfaces while preserving the integrity of the implant's passive protective layer.
Targeted Immunotherapy Opens New Therapeutic Opportunities
Scientific advances are broadening peri-implantitis treatment beyond mechanical debridement toward localized immune modulation. A comprehensive study published in Frontiers in Immunology identified the CXCL13+ fibroblast to CXCR2+ neutrophil signaling pathway as a major driver of inflammatory bone destruction surrounding dental implants. Building on these findings, researchers outlined targeted therapeutic strategies utilizing localized delivery of specialized pro-resolving mediators (SPMs) through pH-responsive and smart hydrogel systems. These delivery platforms are designed to promote macrophage transition from the inflammatory M1 phenotype to the tissue-repairing M2 phenotype, supporting regeneration while reducing chronic inflammation. This growing emphasis on precision immunotherapy and biomaterial-based drug delivery reflects the industry's shift toward biologically driven peri-implantitis management.
Peri-implantitis Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities
The global Peri-implantitis market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Institut Straumann AG, Dentsply Sirona Inc., Zimmer Biomet Holdings, Inc., Geistlich Pharma AG, Pfizer Inc., Envista Holdings Corporation (Nobel Biocare), Henry Schein, Inc., Cadila Pharmaceuticals Ltd., Osstem Implant Co., Ltd., BIOLASE, Inc.. The Peri-implantitis market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Peri-implantitis industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-
Leading companies in Peri-implantitis industry include- Institut Straumann AG, Dentsply Sirona Inc., Zimmer Biomet Holdings, Inc., Geistlich Pharma AG, Pfizer Inc., Envista Holdings Corporation (Nobel Biocare), Henry Schein, Inc., Cadila Pharmaceuticals Ltd., Osstem Implant Co., Ltd., BIOLASE, Inc.. The Peri-implantitis market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.
What to expect in US Peri-implantitis Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034
The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Peri-implantitis market remains one of the strongest-performing segments in the country.
The US Peri-implantitis Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Peri-implantitis market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Peri-implantitis industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.
Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Peri-implantitis markets
Canada's strong Peri-implantitis sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Peri-implantitis market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.
Germany Peri-implantitis Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.
Germany continues to remain the largest Peri-implantitis market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Peri-implantitis population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Peri-implantitis industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Peri-implantitis market outlook.
France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Peri-implantitis sales through 2034
France Peri-implantitis companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.
UK Peri-implantitis Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain
Small high-need consumer segments remain key priority of Peri-implantitis distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or ?280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was ?49 billion (14.1%) and voluntary health insurance was ?9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.
China Peri-implantitis Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years
China Peri-implantitis market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Peri-implantitis industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Peri-implantitis industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.
India Peri-implantitis Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India
Indian Peri-implantitis market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.
Brazil Peri-implantitis market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities
Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.
Middle East and Africa Peri-implantitis Industry Trends and Perspectives to 2034
According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.
Peri-implantitis Market Segmentation
By Method Type
Surgical
Non-Surgical
By End-User
Hospitals
Dental Clinics
Others
Leading Companies in Peri-implantitis Industry (2026)
Institut Straumann AG
Dentsply Sirona Inc.
Zimmer Biomet Holdings, Inc.
Geistlich Pharma AG
Pfizer Inc.
Envista Holdings Corporation (Nobel Biocare)
Henry Schein, Inc.
Cadila Pharmaceuticals Ltd.
Osstem Implant Co., Ltd.
BIOLASE, Inc.
Countries Included
The Peri-implantitis market report provides detailed analysis and outlook of Peri-implantitis segments including By Method Type (Surgical, Non-Surgical), By End-User (Hospitals, Dental Clinics, Others) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.
Peri-Implantitis Industry Overview
Advanced Implant Decontamination and Targeted Therapies Are Transforming Peri-Implantitis Management
The peri-implantitis industry is evolving through the development of minimally invasive implant decontamination technologies, precision immunomodulatory therapies, and biologically targeted treatment strategies. Clinical research is increasingly focused on preserving dental implants by eliminating pathogenic biofilms while minimizing damage to implant surfaces and surrounding tissues. At the same time, advances in molecular biology are enabling the development of localized therapies that address the inflammatory mechanisms responsible for peri-implant bone loss. These innovations are supporting more predictable treatment outcomes and expanding therapeutic options for managing one of the most significant complications associated with dental implant therapy.
Electrolytic Implant Surface Decontamination Gains Clinical Momentum
The industry is witnessing growing adoption of advanced electrolytic technologies designed to improve implant surface cleaning without mechanical damage. Istanbul University expanded its randomized controlled clinical trial evaluating the GalvoSurge system as an adjunctive treatment for peri-implantitis compared with conventional titanium brushes and hydrogen peroxide flap procedures. The study measures clinical outcomes including probing pocket depth, bleeding on probing, and radiographic bone levels over a 24-month follow-up period. Supporting this trend, Straumann Group expanded commercial availability of the GalvoSurge implant care system throughout North America and Europe. The technology generates a localized hydrogen burst through an electrolytic fluid system that removes complex subgingival bacterial biofilms from titanium implant surfaces while preserving the integrity of the implant's passive protective layer.
Targeted Immunotherapy Opens New Therapeutic Opportunities
Scientific advances are broadening peri-implantitis treatment beyond mechanical debridement toward localized immune modulation. A comprehensive study published in Frontiers in Immunology identified the CXCL13+ fibroblast to CXCR2+ neutrophil signaling pathway as a major driver of inflammatory bone destruction surrounding dental implants. Building on these findings, researchers outlined targeted therapeutic strategies utilizing localized delivery of specialized pro-resolving mediators (SPMs) through pH-responsive and smart hydrogel systems. These delivery platforms are designed to promote macrophage transition from the inflammatory M1 phenotype to the tissue-repairing M2 phenotype, supporting regeneration while reducing chronic inflammation. This growing emphasis on precision immunotherapy and biomaterial-based drug delivery reflects the industry's shift toward biologically driven peri-implantitis management.
Peri-implantitis Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities
The global Peri-implantitis market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Institut Straumann AG, Dentsply Sirona Inc., Zimmer Biomet Holdings, Inc., Geistlich Pharma AG, Pfizer Inc., Envista Holdings Corporation (Nobel Biocare), Henry Schein, Inc., Cadila Pharmaceuticals Ltd., Osstem Implant Co., Ltd., BIOLASE, Inc.. The Peri-implantitis market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Peri-implantitis industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-
- Growth Peri-implantitis Market size outlook across 3 scenarios- High growth, reference, and Low growth cases
- Market Trends, Drivers, Potential Opportunities, and Challenges faced by Peri-implantitis companies
- Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry
- Detailed SWOT Analysis of global and regional Peri-implantitis markets
- Competitive analysis including business description, product analysis, and financial profiles
- Key country specific analysis detailing key factors shaping the short-term and long-term outlook
- Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements
Leading companies in Peri-implantitis industry include- Institut Straumann AG, Dentsply Sirona Inc., Zimmer Biomet Holdings, Inc., Geistlich Pharma AG, Pfizer Inc., Envista Holdings Corporation (Nobel Biocare), Henry Schein, Inc., Cadila Pharmaceuticals Ltd., Osstem Implant Co., Ltd., BIOLASE, Inc.. The Peri-implantitis market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.
What to expect in US Peri-implantitis Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034
The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Peri-implantitis market remains one of the strongest-performing segments in the country.
The US Peri-implantitis Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Peri-implantitis market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Peri-implantitis industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.
Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Peri-implantitis markets
Canada's strong Peri-implantitis sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Peri-implantitis market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.
Germany Peri-implantitis Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.
Germany continues to remain the largest Peri-implantitis market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Peri-implantitis population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Peri-implantitis industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Peri-implantitis market outlook.
France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Peri-implantitis sales through 2034
France Peri-implantitis companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.
UK Peri-implantitis Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain
Small high-need consumer segments remain key priority of Peri-implantitis distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or ?280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was ?49 billion (14.1%) and voluntary health insurance was ?9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.
China Peri-implantitis Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years
China Peri-implantitis market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Peri-implantitis industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Peri-implantitis industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.
India Peri-implantitis Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India
Indian Peri-implantitis market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.
Brazil Peri-implantitis market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities
Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.
Middle East and Africa Peri-implantitis Industry Trends and Perspectives to 2034
According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.
Peri-implantitis Market Segmentation
By Method Type
Surgical
Non-Surgical
By End-User
Hospitals
Dental Clinics
Others
Leading Companies in Peri-implantitis Industry (2026)
Institut Straumann AG
Dentsply Sirona Inc.
Zimmer Biomet Holdings, Inc.
Geistlich Pharma AG
Pfizer Inc.
Envista Holdings Corporation (Nobel Biocare)
Henry Schein, Inc.
Cadila Pharmaceuticals Ltd.
Osstem Implant Co., Ltd.
BIOLASE, Inc.
Countries Included
- North America- US, Canada, Mexico
- Europe- Germany, France, UK, Spain, Italy, Nordics, Others
- Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others
- Latin America- Brazil, Argentina, Others
- Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa
- Get Free print authentication across single, multi, and global licenses
- Free Accompanying excel spreadsheet with complete quantitative data
- Free 2-day consulting support from the lead analyst of the team that developed the report
- Gain clear understanding of current market conditions across 20 countries and plan your decisions accordingly
- Understand competitive profiles of the leading 15 companies in the Electrosurgical Generators industry
- Stay ahead of competition through a detailed analysis of recent market developments
- Make trusted decisions building on our 10-year experience in developing reports on Electrosurgical Generators industry
CHAPTER 1- EXECUTIVE SUMMARY
1.1. Market Snapshot: Market Size, CAGR, and Growth Outlook to 2034
1.2. Key Industry Highlights, 2026
1.3. Premium Market Insights
1.3.1. Potential Peri-implantitis Market Types and Applications
1.3.2. Fastest Growing Countries Over the forecast period
1.4. Market Scope and Segmentation
1.4.1. Key Market Segments
1.4.2. Key Countries and Regions
1.4.3. Top Companies in the Peri-implantitis Industry
1.5. Macroeconomic and Demographic Outlook
1.5.1. GDP Outlook by Top 20 Countries, 2010- 2040
1.5.2. Population Forecast by Country, 2010- 2040
1.5.3. Inflation Trends in Leading Countries
1.6. Impact of Trade Policies, Regulations, and Sustainability
1.6.1. Trade tariffs and localization requirements
1.6.2. ESG and sustainability pressures
1.6.3. Compliance-driven structural changes in the value chain
CHAPTER 2- RESEARCH METHODOLOGY
2.1. Report Coverage
2.2. Secondary Research
2.3. Primary Research
2.4. Data Triangulation
2.5. Market Modeling and Forecasting
CHAPTER 3- GLOBAL PERI-IMPLANTITIS MARKET TRENDS, GROWTH DRIVERS, CHALLENGES, AND OPPORTUNITIES THROUGH 2034
3.1. An Introduction to Global Peri-implantitis Markets in 2026
3.2. Global Historic and Forecast Peri-implantitis Market Size Outlook, USD Million, 2021- 2034
3.3. Annual Market Size Growth Rate (Y-o-Y), %, 2021-2034
3.4. Market Dynamics
3.4.1. Key Peri-implantitis Market Driving Forces and Their Impact on Market Outlook
3.4.2. Short and Long-Term Trends and Insights Shaping the Future
3.4.3. Potential Peri-implantitis Market Opportunities for Industry Stakeholders
3.4.4. Potential Challenges across Peri-implantitis Value Chain
CHAPTER 4- PERI-IMPLANTITIS MARKET COMPETITIVE LANDSCAPE, STRATEGIC ANALYSIS, AND VALUE CHAIN ASSESSMENT
4.1. Porter’s Five Forces Analysis
4.1.1. Bargaining Power of Buyers
4.1.2. Bargaining Power of Suppliers
4.1.3. Threat of Substitutes
4.1.4. Threat of New Entrants
4.1.5. Intensity of Competitive Rivalry
4.1.6. Market Attractiveness Analysis by Segment
4.1.7. Market Attractiveness Analysis by Region
4.2. Competitive Landscape
4.2.1 Market Share Analysis of Leading Peri-implantitis Companies
4.2.2 Recent Strategic Developments
4.2.3 Mergers, Acquisitions, and Partnerships
4.2.4 Product Launches and Innovation Trends
4.2.5 Key Success Factors
4.3. Value Chain Analysis
4.3.1. Key Value Chain Segments
4.3.2. Dominant players by value-chain stage
4.4. SWOT Analysis
4.4.1. Key Strengths and Opportunities
4.4.2. Major Weaknesses and Threats
4.5 Technology Roadmap
4.6 Regulatory and Reimbursement Landscape
CHAPTER 5- PERI-IMPLANTITIS MARKET OUTLOOK BY SEGMENTS
5.1. Market Size Outlook by Type, USD Million, 2021- 2025 and 2026-2034
5.2. Market Size Outlook by Application, USD Million, 2021- 2025 and 2026-2034
5.3. Market Size Outlook by Country, USD Million, 2021- 2025 and 2026-2034
By Method Type
Surgical
Non-Surgical
By End-User
Hospitals
Dental Clinics
Others
CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK
6.1. Base Case Scenario
6.1.1. Definitions and Insights
6.1.2. Market Size Outlook to 2034
6.2. Low Growth Case Scenario
6.2.1. Definitions and Insights
6.2.2. Market Size Outlook to 2034
6.3. High Growth Case Scenario
6.3.1. Definitions and Insights
6.3.2. Market Size Outlook to 2034
CHAPTER 7- NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE ANALYSIS AND OUTLOOK
7.1. North America Peri-implantitis Market Overview, 2026
7.2. Leading Companies Operating in North America
7.3. Key Industry Statistics, 2026
7.4. North America Peri-implantitis Market Trends and Growth Opportunities to 2034
7.5. North America Peri-implantitis Market Size Outlook by Type
7.6. North America Peri-implantitis Market Size Outlook by Application
7.7. North America Peri-implantitis Market Size Outlook by Country
7.8. United States
7.8.1. Key Statistics
7.8.2. The US Peri-implantitis Market Size Outlook, 2021- 2034
7.8.3. Key Market Drivers and Industry Developments in the US Peri-implantitis Companies
7.9. Canada
7.9.1. Key Statistics
7.9.2. Canada Peri-implantitis Market Size Outlook, 2021- 2034
7.9.3. Key Market Drivers and Industry Developments in Canada Peri-implantitis Companies
7.10. Mexico
7.10.1. Key Statistics
7.10.2. Mexico Peri-implantitis Market Size Outlook, 2021- 2034
7.10.3. Key Market Drivers and Industry Developments in Mexico Peri-implantitis Companies
CHAPTER 8- EUROPE PERI-IMPLANTITIS MARKET SIZE ANALYSIS AND OUTLOOK
8.1. Europe Peri-implantitis Market Overview, 2026
8.2. Leading Companies Operating in Europe
8.3. Key Industry Statistics, 2026
8.4. Europe Peri-implantitis Market Trends and Growth Opportunities to 2034
8.5. Europe Peri-implantitis Market Size Outlook by Type
8.6. Europe Peri-implantitis Market Size Outlook by Application
8.7. Europe Peri-implantitis Market Size Outlook by Country
8.8. Germany
8.8.1. Key Statistics
8.8.2. Germany Peri-implantitis Market Size Outlook, 2021- 2034
8.8.3. Key Market Drivers and Industry Developments in Germany Peri-implantitis Companies
8.9. France
8.9.1. Key Statistics
8.9.2. France Peri-implantitis Market Size Outlook, 2021- 2034
8.9.3. Key Market Drivers and Industry Developments in France Peri-implantitis Companies
8.10. United Kingdom
8.10.1. Key Statistics
8.10.2. United Kingdom Peri-implantitis Market Size Outlook, 2021- 2034
8.10.3. Key Market Drivers and Industry Developments in the UK Peri-implantitis Companies
8.11. Spain
8.11.1. Key Statistics
8.11.2. Spain Peri-implantitis Market Size Outlook, 2021- 2034
8.11.3. Key Market Drivers and Industry Developments in Spain Peri-implantitis Companies
8.12. Italy
8.12.1. Key Statistics
8.12.2. Italy Peri-implantitis Market Size Outlook, 2021- 2034
8.12.3. Key Market Drivers and Industry Developments in Italy Peri-implantitis Companies
8.13. Rest of Europe
8.13.1. Key Statistics
8.13.2. Rest of Europe Peri-implantitis Market Size Outlook, 2021- 2034
8.13.3. Key Market Drivers and Industry Developments in Rest of Europe Peri-implantitis Companies
CHAPTER 9- ASIA PACIFIC PERI-IMPLANTITIS MARKET SIZE ANALYSIS AND OUTLOOK
9.1. Asia Pacific Peri-implantitis Market Overview, 2026
9.2. Leading Companies Operating in Asia Pacific
9.3. Key Industry Statistics, 2026
9.4. Asia Pacific Peri-implantitis Market Trends and Growth Opportunities to 2034
9.5. Asia Pacific Peri-implantitis Market Size Outlook by Type
9.6. Asia Pacific Peri-implantitis Market Size Outlook by Application
9.7. Asia Pacific Peri-implantitis Market Size Outlook by Country
9.8. China
9.8.1. Key Statistics
9.8.2. China Peri-implantitis Market Size Outlook, 2021- 2034
9.8.3. Key Market Drivers and Industry Developments in China Peri-implantitis Companies
9.9. Japan
9.9.1. Key Statistics
9.9.2. Japan Peri-implantitis Market Size Outlook, 2021- 2034
9.9.3. Key Market Drivers and Industry Developments in Japan Peri-implantitis Companies
9.10. India
9.10.1. Key Statistics
9.10.2. India Peri-implantitis Market Size Outlook, 2021- 2034
9.10.3. Key Market Drivers and Industry Developments in India Peri-implantitis Companies
9.11. South Korea
9.11.1. Key Statistics
9.11.2. South Korea Peri-implantitis Market Size Outlook, 2021- 2034
9.11.3. Key Market Drivers and Industry Developments in South Korea Peri-implantitis Companies
9.12. Australia
9.12.1. Key Statistics
9.12.2. Australia Peri-implantitis Market Size Outlook, 2021- 2034
9.12.3. Key Market Drivers and Industry Developments in Australia Peri-implantitis Companies
9.13. Southeast Asia
9.13.1. Key Statistics
9.13.2. Southeast Asia Peri-implantitis Market Size Outlook, 2021- 2034
9.13.3. Key Market Drivers and Industry Developments in Southeast Asia Peri-implantitis Companies
CHAPTER 10- SOUTH AND CENTRAL AMERICA PERI-IMPLANTITIS MARKET SIZE ANALYSIS AND OUTLOOK
10.1. South and Central America Peri-implantitis Market Overview, 2026
10.2. Leading Companies Operating in South and Central America
10.3. Key Industry Statistics, 2026
10.4. South and Central America Peri-implantitis Market Trends and Growth Opportunities to 2034
10.5. South and Central America Peri-implantitis Market Size Outlook by Type
10.6. South and Central America Peri-implantitis Market Size Outlook by Application
10.7. South and Central America Peri-implantitis Market Size Outlook by Country
10.8. Brazil
10.8.1. Key Statistics
10.8.2. Brazil Peri-implantitis Market Size Outlook, 2021- 2034
10.8.3. Key Market Drivers and Industry Developments in Brazil Peri-implantitis Companies
10.9. Argentina
10.9.1. Key Statistics
10.9.2. Argentina Peri-implantitis Market Size Outlook, 2021- 2034
10.9.3. Key Market Drivers and Industry Developments in Argentina Peri-implantitis Companies
10.10. Rest of Latin America
10.10.1. Key Statistics
10.10.2. Rest of Latin America Peri-implantitis Market Size Outlook, 2021- 2034
10.10.3. Key Market Drivers and Industry Developments in Rest of Latin America Peri-implantitis Companies
CHAPTER 11- MIDDLE EAST AND AFRICA PERI-IMPLANTITIS MARKET SIZE ANALYSIS AND OUTLOOK
11.1. Middle East and Africa Peri-implantitis Market Overview, 2026
11.2. Leading Companies Operating in Middle East and Africa
11.3. Key Industry Statistics, 2026
11.4. Middle East and Africa Peri-implantitis Market Trends and Growth Opportunities to 2034
11.5. Middle East and Africa Peri-implantitis Market Size Outlook by Type
11.6. Middle East and Africa Peri-implantitis Market Size Outlook by Application
11.7. Middle East and Africa Peri-implantitis Market Size Outlook by Country
11.8. Saudi Arabia
11.8.1. Key Statistics
11.8.2. Saudi Arabia Peri-implantitis Market Size Outlook, 2021- 2034
11.8.3. Key Market Drivers and Industry Developments in Saudi Arabia Peri-implantitis Companies
11.9. United Arab Emirates
11.9.1. Key Statistics
11.9.2. The UAE Peri-implantitis Market Size Outlook, 2021- 2034
11.9.3. Key Market Drivers and Industry Developments in the UAE Peri-implantitis Companies
11.10. Africa
11.10.1. Key Statistics
11.10.2. Africa Peri-implantitis Market Size Outlook, 2021- 2034
11.10.3. Key Market Drivers and Industry Developments in Africa Peri-implantitis Companies
CHAPTER 12- COMPANY PROFILES
12.1. Top Companies in Peri-implantitis Industry
Institut Straumann AG
Dentsply Sirona Inc.
Zimmer Biomet Holdings, Inc.
Geistlich Pharma AG
Pfizer Inc.
Envista Holdings Corporation (Nobel Biocare)
Henry Schein, Inc.
Cadila Pharmaceuticals Ltd.
Osstem Implant Co., Ltd.
BIOLASE, Inc.
12.2. Business Description
12.3. SWOT Profiles
12.4. Products and Services
CHAPTER 13- APPENDIX
Glossary of Terms
Research Methodology & Data Sources
Conclusion & Strategic Recommendations
1.1. Market Snapshot: Market Size, CAGR, and Growth Outlook to 2034
1.2. Key Industry Highlights, 2026
1.3. Premium Market Insights
1.3.1. Potential Peri-implantitis Market Types and Applications
1.3.2. Fastest Growing Countries Over the forecast period
1.4. Market Scope and Segmentation
1.4.1. Key Market Segments
1.4.2. Key Countries and Regions
1.4.3. Top Companies in the Peri-implantitis Industry
1.5. Macroeconomic and Demographic Outlook
1.5.1. GDP Outlook by Top 20 Countries, 2010- 2040
1.5.2. Population Forecast by Country, 2010- 2040
1.5.3. Inflation Trends in Leading Countries
1.6. Impact of Trade Policies, Regulations, and Sustainability
1.6.1. Trade tariffs and localization requirements
1.6.2. ESG and sustainability pressures
1.6.3. Compliance-driven structural changes in the value chain
CHAPTER 2- RESEARCH METHODOLOGY
2.1. Report Coverage
2.2. Secondary Research
2.3. Primary Research
2.4. Data Triangulation
2.5. Market Modeling and Forecasting
CHAPTER 3- GLOBAL PERI-IMPLANTITIS MARKET TRENDS, GROWTH DRIVERS, CHALLENGES, AND OPPORTUNITIES THROUGH 2034
3.1. An Introduction to Global Peri-implantitis Markets in 2026
3.2. Global Historic and Forecast Peri-implantitis Market Size Outlook, USD Million, 2021- 2034
3.3. Annual Market Size Growth Rate (Y-o-Y), %, 2021-2034
3.4. Market Dynamics
3.4.1. Key Peri-implantitis Market Driving Forces and Their Impact on Market Outlook
3.4.2. Short and Long-Term Trends and Insights Shaping the Future
3.4.3. Potential Peri-implantitis Market Opportunities for Industry Stakeholders
3.4.4. Potential Challenges across Peri-implantitis Value Chain
CHAPTER 4- PERI-IMPLANTITIS MARKET COMPETITIVE LANDSCAPE, STRATEGIC ANALYSIS, AND VALUE CHAIN ASSESSMENT
4.1. Porter’s Five Forces Analysis
4.1.1. Bargaining Power of Buyers
4.1.2. Bargaining Power of Suppliers
4.1.3. Threat of Substitutes
4.1.4. Threat of New Entrants
4.1.5. Intensity of Competitive Rivalry
4.1.6. Market Attractiveness Analysis by Segment
4.1.7. Market Attractiveness Analysis by Region
4.2. Competitive Landscape
4.2.1 Market Share Analysis of Leading Peri-implantitis Companies
4.2.2 Recent Strategic Developments
4.2.3 Mergers, Acquisitions, and Partnerships
4.2.4 Product Launches and Innovation Trends
4.2.5 Key Success Factors
4.3. Value Chain Analysis
4.3.1. Key Value Chain Segments
4.3.2. Dominant players by value-chain stage
4.4. SWOT Analysis
4.4.1. Key Strengths and Opportunities
4.4.2. Major Weaknesses and Threats
4.5 Technology Roadmap
4.6 Regulatory and Reimbursement Landscape
CHAPTER 5- PERI-IMPLANTITIS MARKET OUTLOOK BY SEGMENTS
5.1. Market Size Outlook by Type, USD Million, 2021- 2025 and 2026-2034
5.2. Market Size Outlook by Application, USD Million, 2021- 2025 and 2026-2034
5.3. Market Size Outlook by Country, USD Million, 2021- 2025 and 2026-2034
By Method Type
Surgical
Non-Surgical
By End-User
Hospitals
Dental Clinics
Others
CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK
6.1. Base Case Scenario
6.1.1. Definitions and Insights
6.1.2. Market Size Outlook to 2034
6.2. Low Growth Case Scenario
6.2.1. Definitions and Insights
6.2.2. Market Size Outlook to 2034
6.3. High Growth Case Scenario
6.3.1. Definitions and Insights
6.3.2. Market Size Outlook to 2034
CHAPTER 7- NORTH AMERICA PERI-IMPLANTITIS MARKET SIZE ANALYSIS AND OUTLOOK
7.1. North America Peri-implantitis Market Overview, 2026
7.2. Leading Companies Operating in North America
7.3. Key Industry Statistics, 2026
7.4. North America Peri-implantitis Market Trends and Growth Opportunities to 2034
7.5. North America Peri-implantitis Market Size Outlook by Type
7.6. North America Peri-implantitis Market Size Outlook by Application
7.7. North America Peri-implantitis Market Size Outlook by Country
7.8. United States
7.8.1. Key Statistics
7.8.2. The US Peri-implantitis Market Size Outlook, 2021- 2034
7.8.3. Key Market Drivers and Industry Developments in the US Peri-implantitis Companies
7.9. Canada
7.9.1. Key Statistics
7.9.2. Canada Peri-implantitis Market Size Outlook, 2021- 2034
7.9.3. Key Market Drivers and Industry Developments in Canada Peri-implantitis Companies
7.10. Mexico
7.10.1. Key Statistics
7.10.2. Mexico Peri-implantitis Market Size Outlook, 2021- 2034
7.10.3. Key Market Drivers and Industry Developments in Mexico Peri-implantitis Companies
CHAPTER 8- EUROPE PERI-IMPLANTITIS MARKET SIZE ANALYSIS AND OUTLOOK
8.1. Europe Peri-implantitis Market Overview, 2026
8.2. Leading Companies Operating in Europe
8.3. Key Industry Statistics, 2026
8.4. Europe Peri-implantitis Market Trends and Growth Opportunities to 2034
8.5. Europe Peri-implantitis Market Size Outlook by Type
8.6. Europe Peri-implantitis Market Size Outlook by Application
8.7. Europe Peri-implantitis Market Size Outlook by Country
8.8. Germany
8.8.1. Key Statistics
8.8.2. Germany Peri-implantitis Market Size Outlook, 2021- 2034
8.8.3. Key Market Drivers and Industry Developments in Germany Peri-implantitis Companies
8.9. France
8.9.1. Key Statistics
8.9.2. France Peri-implantitis Market Size Outlook, 2021- 2034
8.9.3. Key Market Drivers and Industry Developments in France Peri-implantitis Companies
8.10. United Kingdom
8.10.1. Key Statistics
8.10.2. United Kingdom Peri-implantitis Market Size Outlook, 2021- 2034
8.10.3. Key Market Drivers and Industry Developments in the UK Peri-implantitis Companies
8.11. Spain
8.11.1. Key Statistics
8.11.2. Spain Peri-implantitis Market Size Outlook, 2021- 2034
8.11.3. Key Market Drivers and Industry Developments in Spain Peri-implantitis Companies
8.12. Italy
8.12.1. Key Statistics
8.12.2. Italy Peri-implantitis Market Size Outlook, 2021- 2034
8.12.3. Key Market Drivers and Industry Developments in Italy Peri-implantitis Companies
8.13. Rest of Europe
8.13.1. Key Statistics
8.13.2. Rest of Europe Peri-implantitis Market Size Outlook, 2021- 2034
8.13.3. Key Market Drivers and Industry Developments in Rest of Europe Peri-implantitis Companies
CHAPTER 9- ASIA PACIFIC PERI-IMPLANTITIS MARKET SIZE ANALYSIS AND OUTLOOK
9.1. Asia Pacific Peri-implantitis Market Overview, 2026
9.2. Leading Companies Operating in Asia Pacific
9.3. Key Industry Statistics, 2026
9.4. Asia Pacific Peri-implantitis Market Trends and Growth Opportunities to 2034
9.5. Asia Pacific Peri-implantitis Market Size Outlook by Type
9.6. Asia Pacific Peri-implantitis Market Size Outlook by Application
9.7. Asia Pacific Peri-implantitis Market Size Outlook by Country
9.8. China
9.8.1. Key Statistics
9.8.2. China Peri-implantitis Market Size Outlook, 2021- 2034
9.8.3. Key Market Drivers and Industry Developments in China Peri-implantitis Companies
9.9. Japan
9.9.1. Key Statistics
9.9.2. Japan Peri-implantitis Market Size Outlook, 2021- 2034
9.9.3. Key Market Drivers and Industry Developments in Japan Peri-implantitis Companies
9.10. India
9.10.1. Key Statistics
9.10.2. India Peri-implantitis Market Size Outlook, 2021- 2034
9.10.3. Key Market Drivers and Industry Developments in India Peri-implantitis Companies
9.11. South Korea
9.11.1. Key Statistics
9.11.2. South Korea Peri-implantitis Market Size Outlook, 2021- 2034
9.11.3. Key Market Drivers and Industry Developments in South Korea Peri-implantitis Companies
9.12. Australia
9.12.1. Key Statistics
9.12.2. Australia Peri-implantitis Market Size Outlook, 2021- 2034
9.12.3. Key Market Drivers and Industry Developments in Australia Peri-implantitis Companies
9.13. Southeast Asia
9.13.1. Key Statistics
9.13.2. Southeast Asia Peri-implantitis Market Size Outlook, 2021- 2034
9.13.3. Key Market Drivers and Industry Developments in Southeast Asia Peri-implantitis Companies
CHAPTER 10- SOUTH AND CENTRAL AMERICA PERI-IMPLANTITIS MARKET SIZE ANALYSIS AND OUTLOOK
10.1. South and Central America Peri-implantitis Market Overview, 2026
10.2. Leading Companies Operating in South and Central America
10.3. Key Industry Statistics, 2026
10.4. South and Central America Peri-implantitis Market Trends and Growth Opportunities to 2034
10.5. South and Central America Peri-implantitis Market Size Outlook by Type
10.6. South and Central America Peri-implantitis Market Size Outlook by Application
10.7. South and Central America Peri-implantitis Market Size Outlook by Country
10.8. Brazil
10.8.1. Key Statistics
10.8.2. Brazil Peri-implantitis Market Size Outlook, 2021- 2034
10.8.3. Key Market Drivers and Industry Developments in Brazil Peri-implantitis Companies
10.9. Argentina
10.9.1. Key Statistics
10.9.2. Argentina Peri-implantitis Market Size Outlook, 2021- 2034
10.9.3. Key Market Drivers and Industry Developments in Argentina Peri-implantitis Companies
10.10. Rest of Latin America
10.10.1. Key Statistics
10.10.2. Rest of Latin America Peri-implantitis Market Size Outlook, 2021- 2034
10.10.3. Key Market Drivers and Industry Developments in Rest of Latin America Peri-implantitis Companies
CHAPTER 11- MIDDLE EAST AND AFRICA PERI-IMPLANTITIS MARKET SIZE ANALYSIS AND OUTLOOK
11.1. Middle East and Africa Peri-implantitis Market Overview, 2026
11.2. Leading Companies Operating in Middle East and Africa
11.3. Key Industry Statistics, 2026
11.4. Middle East and Africa Peri-implantitis Market Trends and Growth Opportunities to 2034
11.5. Middle East and Africa Peri-implantitis Market Size Outlook by Type
11.6. Middle East and Africa Peri-implantitis Market Size Outlook by Application
11.7. Middle East and Africa Peri-implantitis Market Size Outlook by Country
11.8. Saudi Arabia
11.8.1. Key Statistics
11.8.2. Saudi Arabia Peri-implantitis Market Size Outlook, 2021- 2034
11.8.3. Key Market Drivers and Industry Developments in Saudi Arabia Peri-implantitis Companies
11.9. United Arab Emirates
11.9.1. Key Statistics
11.9.2. The UAE Peri-implantitis Market Size Outlook, 2021- 2034
11.9.3. Key Market Drivers and Industry Developments in the UAE Peri-implantitis Companies
11.10. Africa
11.10.1. Key Statistics
11.10.2. Africa Peri-implantitis Market Size Outlook, 2021- 2034
11.10.3. Key Market Drivers and Industry Developments in Africa Peri-implantitis Companies
CHAPTER 12- COMPANY PROFILES
12.1. Top Companies in Peri-implantitis Industry
Institut Straumann AG
Dentsply Sirona Inc.
Zimmer Biomet Holdings, Inc.
Geistlich Pharma AG
Pfizer Inc.
Envista Holdings Corporation (Nobel Biocare)
Henry Schein, Inc.
Cadila Pharmaceuticals Ltd.
Osstem Implant Co., Ltd.
BIOLASE, Inc.
12.2. Business Description
12.3. SWOT Profiles
12.4. Products and Services
CHAPTER 13- APPENDIX
Glossary of Terms
Research Methodology & Data Sources
Conclusion & Strategic Recommendations
